Petros Pharmaceuticals (Petros Pharmaceuticals) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of May. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Petros Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Petros Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

Petros Pharmaceuticals (NAS:PTPI) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Petros Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.petrospharma.com

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley	director	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman	director, 10 percent owner
Jcp Iii Sm Aiv, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan	officer: Chief Financial Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor	officer: Pres. & Chief Comm. Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek	officer: President, Timm Medical	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold	officer: Prin. Acct. Off/Prin. Fin. Off	200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726